US Edition
Hengrui Pharma and GSK Enter Agreements to Develop up to 12 Innovative Medicines Across Respiratory, Immunology & Inflammation and Oncology
- On July 28, 2025, GSK and Hengrui Pharma revealed agreements granting GSK rights, outside Greater China, to advance as many as 12 novel medicines across respiratory, immunology, inflammation, and oncology therapeutic areas.
- The deal arose from GSK's need to strengthen its pipeline ahead of patent expirations and reflects growing interest in China's biotech sector, which saw major licensing growth by 2024 and 2025.
- Hengrui will lead early development through Phase I trials involving international patients, while GSK will pay $500 million upfront and hold options to further develop and commercialize the programs.
- GSK’s Chief Scientific Officer Tony Wood expressed enthusiasm about the new collaboration with Hengrui Pharma, noting that these deals enhance GSK’s broad pipeline. The agreement includes upfront payments of $500 million and could total up to $12 billion if all milestones and program options are fulfilled.
- The collaboration enables GSK to broaden its range of COPD therapies, addressing a disease responsible for a significant number of deaths worldwide and impacting over 300 million individuals, thereby advancing its goal to provide treatments for patients across the broadest spectrum of the condition.
Insights by Ground AI
Does this summary seem wrong?
81 Articles
81 Articles
GSK pays $500M upfront for rights to series of Hengrui drugs
LONDON — GSK said Monday it would pay $500 million upfront for rights to an experimental COPD drug from Jiangsu Hengrui Pharmaceuticals, the latest example of a pharma company turning to a Chinese firm to build out its pipeline. The deal also includes licensing options for 11 other Hengrui medicines, including those in development in immunology and oncology. If all programs are optioned and all milestones are met, the pact could be worth up to …
·Boston, United States
Read Full Article
Coverage Details
Total News Sources81
Leaning Left9Leaning Right9Center26Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 20%
C 59%
R 20%
Factuality
To view factuality data please Upgrade to Premium
